Transforming Fatty Liver Treatment Through Precision RNAi
A first-in-class RNAi therapy targeting an undruggable liver protein – built on 20 years of metabolic disease research.
About Us
Our therapeutic programme addresses metabolic dysfunction–associated steatotic liver disease (MASLD/MASH) with a novel, liver-directed mechanism. With potential expansion into type-2 diabetes, our platform offers pharma partners both innovation and pipeline diversification.
The Problem
Metabolic liver disease is one of the fastest-growing global health challenges.
- Up to 2 billion people worldwide are affected by fatty liver disease.
- Disease progression can lead to cirrhosis, liver failure, and cardiovascular complications.
- Only two approved therapies currently exist – both with limitiations in effiacy and tolerability.
- The clinical and commercial need for improved treatments remains substantial.
We aim to use RNA interference (RNAi) technology to our target protein, directly in the liver, where previous small molecule discovery attempts found this protein to be practically undruggable.
Our Solution
We are developing a liver-directed RNA interference (RNAi) therapeutic that silences a disease-driven protein previously considered inaccessible to traditional drug discovery approaches.
Why This Matters
- Directly targets the liver – the site of disease
- Bypasses limitations of small molecule druggability
- Builds on 20 years of mechanistic metabolic research
- Potential expanision into type-2 diabetes
- Strong strategic fit for pharma pipeline expansion
Our approach is designed to improve metabolic liver pathology, address insulin resistance and offer a differentiated mechanism in a crowded field.
The Team
We are seeking pharmaceutical and biotech partners interested in novel metabolic mechanisms and RNA-based therapeutics. We offer strong academic validation, translational rationale, and potential expansion beyond liver disease into type-2 diabetes, providing both innovation and risk diversification.
Please connect via LinkedIn if you’d like to reach out to us to find out more about our work.
Prof. Mirela Delibegovic
Entrepreneurial Lead
Dr. Nimesh Mody
Principal Scientific Advisor (PSA)
Dr Paul Nioi
Industry Advisor
Partner with Us to Redefine Liver Disease Treatment
For partnership enquiries or further information about our programme, please contact our team to arrange a discussion.